Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure (GFM-AZA-VOR)

This study has suspended participant recruitment.
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Groupe Francophone des Myelodysplasies
ClinicalTrials.gov Identifier:
NCT01748240
First received: December 7, 2012
Last updated: October 28, 2015
Last verified: April 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: March 2016
  Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)